X0306 4 2019-07-10 1 0001447028 Arbutus Biopharma Corp ABUS 0001311210 Machado Patrick C/O ROIVANT SCIENCES LTD. SUITE 1, 3RD FLOOR, 11-12 ST. JAMES'S SQUARE LONDON X0 SW1Y 4LB UNITED KINGDOM 0 0 0 1 Former 10% Owner This Form 4 relates to the Common Shares, no par value (the "Common Shares"), and the Series A Participating Convertible Preferred Shares (the "Preferred Shares") of Arbutus Biopharma Corporation (the "Issuer"). On July 10, 2019, the board of directors of Roivant Sciences Ltd. ("Roivant") adopted changes to Roivant's internal governance concerning the disposition of the Common Shares and other matters relating to oversight of Roivant's business and governance. Following the amendments adopted on July 10, 2019, disposition of the Common Shares requires either the approval of a majority of Roivant's board, including (i) at least two directors meeting certain independence criteria (each, an "Independent Director" and, collectively, the "Independent Directors") or, (ii) if there is only one Independent Director, that sole Independent Director. The Reporting Person is currently an Independent Director of Roivant. However, the vote of a majority of Roivant's shareholders holding 5% or more of Roivant's shares may override certain decisions of Roivant's board of directors, including with respect to dispositions of Common Shares. As a result of these changes, the Reporting Person is no longer deemed to beneficially own the Common Shares of the Issuer directly owned by Roivant. Roivant's ownership of the Issuer's Common Shares remains unchanged and this filing is not being made as a result of the purchase or sale of Common Shares of the Issuer by any party, including the Reporting Person. /s/ Marianne Romeo Dinsmore, as Attorney-in-Fact 2019-07-15